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We report the first study of the biological effect of fulvestrant on ER positive clinical breast cancer using sequential biopsies
through to progression. Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month)
were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR
and HER2 expression/signaling activity. This series showed good fulvestrant responses (duration of response [DoR]525.8
months; clinical benefit581%). Ki67 fell (p< 0.001) in 79% of tumours by 6 months and lower Ki67 at all preprogression time-
points predicted for longer DoR. ER and PR significantly decreased in all tumours by 6 months (p<0.001), with some declines in
ER (serine 118) phosphorylation and Bcl-2 (p50.007). There were modest HER2 increases (p50.034, 29% tumours) and loss of
any detectable EGFR phosphorylation (p50.024, 50% tumours) and MAP kinase (ERK1/2) phosphorylation (p50.019, 65%
tumours) by 6 months. While ER remained low, there was some recovery of Ki67, Bcl-2 and (weakly) EGFR/MAPK activity in 45–
67% patients at progression. Fulvestrant’s anti-proliferative impact is related to DoR, but while commonly downregulating ER and
indicators of its signaling and depleting EGFR/MAPK signaling in some patients, additional elements must determine response
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Additional Supporting Information may be found in the online version of this article.
Abbreviations: ABC: advanced breast cancer; AF-1: activation function domain-1; AI: aromatase inhibitor; AKT: protein kinase B;
Bcl-2: apoptosis regulator B-Cell CLL/Lymphoma 2; CB: clinical benefit; CI: confidence intervals; CONR/LP: continuing responders/late
progressors (CB tumours with responses exceeding median DoCB); DoCB: duration of response in patients with clinical benefit; DoR:
duration of response in All-patients; EGFR: epidermal growth factor receptor; EP: early progressors (CB tumours progressing prior to
median DoCB); ER: estrogen receptor-alpha; ERK1/2: extracellular signal regulated kinases 1 and 2; GF: growth factor; HER2: receptor
tyrosine-protein kinase erbB-2; HER3: receptor tyrosine-protein kinase erbB-3; HER4: receptor tyrosine-protein kinase erbB-4; IHC:
immunohistochemistry; Ki67: proliferation-related KI-67 antigen; LAPC: locally advanced breast cancer; MAPK: mitogen-activated pro-
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duration. Residual ER at fulvestrant relapse explains reported sensitivity to further endocrine therapies. Occasional modest
treatment-induced HER2 and weakly detectable EGFR/HER2/MAPK signaling at relapse suggests targeting of such activity might
have value alongside fulvestrant in some patients. However, unknown pathways must drive relapse in most. Ki67 has bio-
marker potential to predict fulvestrant outcome and as a quantitative measure of response.
Fulvestrant (FaslodexTM) is a pure anti-estrogen with no
known agonistic activity, contrasting tamoxifen. The steroidal
agent fulvestrant prevents estradiol binding to estrogen
receptor-alpha (ER) to a stronger extent than tamoxifen. It
also has a distinct mode of action that causes severe receptor
conformational changes, promoting receptor degradation and
downregulation of ER protein level and depletion of ER tran-
scriptional activation.1 Clinically, therefore, fulvestrant retains
activity in postmenopausal tamoxifen or nonsteroidal aroma-
tase inhibitor (AI) resistant estrogen receptor positive (ER1)
breast cancers.2–5 Fulvestrant, at 250 mg, had similar time to
progression, survival and response rate to use of tamoxifen/
AIs in Phase III trials.2–4,6 Following observations of dose-
dependent decline in ER after short-term fulvestrant treat-
ment of clinical breast cancer,7 additional studies including
the CONFIRM trial5 provided evidence of further beneﬁt
with fulvestrant at 500 mg in ER1 disease following prior
endocrine failure. Clinical signiﬁcance of fulvestrant is set to
increase further since this anti-hormone also has potential in
neoadjuvant and ﬁrst-line advanced ER1 postmenopausal
disease settings, evidenced by trials including NEWEST8 and
FIRST,9,10 respectively. Further studies are also exploring ful-
vestrant alongside AIs, exempliﬁed by the FACT11 and
SWOG trials.12
Despite its increasing clinical value, de novo and acquired
resistance remains a signiﬁcant problem with fulvestrant.
This disease state is largely unexplored in the clinical setting.
The erbB receptor family members EGFR and HER2, as well
as mitogen-activated protein kinase signaling activity
(MAPK), can be elevated and growth contributory to
acquired fulvestrant resistance in vitro,13,14 although this is
not a unifying feature of all fulvestrant resistant models.15
These can also be reliant on further erbB receptors,16 Src
kinase and PI3K/AKT/mTOR signaling.17,18 Moreover,
growth factor (GF) signaling pathways have been heavily
implicated in tamoxifen and estrogen deprivation resistance
models, where they cross-talk with ER. For example, EGFR/
HER2 and MAPK signaling onto ER, via activation function
domain 1 (AF-1) residue phosphorylation (e.g., serine 118),
can permit either agonistic behaviour of tamoxifen or hyper-
sensitivity to residual estrogens in vitro.19–22 Theoretically,
depletion of ER and thereby cross-talk’s critical “hub” should
occur with fulvestrant, so that the development of resistance
would potentially be delayed and possibly also ER-
independent. Fulvestrant is certainly able to promote ER deg-
radation, decrease ER-regulated proteins (e.g., progesterone
receptor [PR], pS2, cell survival protein Bcl-2) and prolifera-
tion, and delay resistance in ER1 models.23 In short-term
studies (<16weeks) fulvestrant also decreased ER, PR and pS2,
proliferation and (modestly) increased apoptosis in patient
samples.7,8,24,25 Nevertheless, some fulvestrant resistant patients
retain sensitivity to further endocrine challenge.
Clearly, if we are to better understand response and acquired
fulvestrant resistance in patients, it remains important to proﬁle
ER expression/function and GF signaling pathways during long-
term fulvestrant treatment. Indeed, it is our hypothesis that
knowledge of such proﬁles through to fulvestrant resistance
should aid interpretation of various breast cancer trials examin-
ing fulvestrant with anti-GFs, could provide rationale for devel-
opment of new strategies to delay or treat this resistant state,
and may identify predictive biomarkers to maximize beneﬁt
from fulvestrant. Sequential breast cancer biopsies taken from
locally advanced disease with or without metastases, prior to,
during ﬁrst-line fulvestrant treatment and at subsequent relapse
provide an important resource to help achieve this goal.
Here, for the ﬁrst time, we proﬁle the impact of initial (6
weeks) and prolonged (6 months and beyond) fulvestrant treat-
ment (250 mg/month) on key elements of ER and GF signaling
cross-talk and proliferation in clinical ER1 samples. The immu-
nohistochemical (IHC) methodology employed provides an
immediate indication of potential value and feasibility of the
various biomarker assays to predict fulvestrant clinical outcome.
Material and Methods
Sequential core biopsies were obtained from 32 ER1 locally
advanced or systemically advanced breast cancer patients
treated with ﬁrst-line fulvestrant (250 mg/month). Thirty
patients were from FaslodexTM 003 (an open label ﬁrst-line
study to enable exploratory biological investigation; Notting-
ham Research Ethics Committee EC00/191). Two patients
What’s new?
The steroidal drug fulvestrant is a powerful antiestrogen, blocking the estrogen receptor-alpha to a greater extent than tamox-
ifen. However, the development of drug resistance is a considerable problem with fulvestrant. For the first time, the authors
of the present study examined the biological effects of fulvestrant therapy using sequential breast tumor biopsies from
untreated, treated, and relapsed patients. While residual estrogen receptor activity and tumor cell proliferation were detected
at relapse, no meaningful increases were found in EGFR/HER2/MAPK activity. Ki67 expression was associated with duration of
response, indicating promise as a predictive biomarker for fulvestrant outcome.
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(with all sequential biopsies on unblinding) were from Faslo-
dexTM 0025 (a randomized, double blind Phase III trial com-
paring 250 mg fulvestrant with 20 mg tamoxifen as ﬁrst-line
therapy; EC98/239). Table 1 details criteria deﬁning quality
and duration of fulvestrant clinical response. Supporting
Information Table S1a summarizes the patient series includ-
ing baseline disease characteristics and clinical response (pro-
vided on a per case basis in Supporting Information Table
S1b). The patient series showed good fulvestrant responses
with a median duration of response (DoR) of 25.8 (1.8–60.7)
months. Twenty-six patients (81.25%) had clinical beneﬁt
(CB), with a median DoR in CB patients (DoCB) of 29.3
(10.9–60.7) months. Responses to any other treatments fol-
lowing fulvestrant progression were not a component of these
response data. The median duration of overall survival
(reﬂecting impact of ﬁrst-line fulvestrant and any subsequent
disease management) was 35.5 (2.1–71.9) months, with 11
breast cancer-speciﬁc deaths at analysis.
Core biopsies were taken from each tumour using a 14-
gauge needle (AA, JFR, KLC, EG) before commencing fulves-
trant (T1), at 6 weeks (T2) and 6 months (T3) on treatment,
and at disease progression (T4) for routine formalin-ﬁxation
and parafﬁn-embedding. Adequate cellularity (>100 tumour
cells) was ﬁrst veriﬁed in each biopsy (n5 31, 28, 25, 15 sam-
ples at T1-T4, respectively) and cellularity was recorded. IHC
was then performed on 3 lm sections for proliferation (Ki67)
and biomarkers indicative of ER function [ER, PR, Bcl-2, pER
(serine 118 phosphorylated ER)], GF signaling [EGFR and
HER2 expression or activity (Tyr845 and Tyr1248 phosphoryl-
ated pEGFR and pHER2, respectively)] or MAPK activity
[Thr202/Tyr204 pMAPK, detecting phosphorylated MAPK1/3
(ERK1/2)]. HercepTestTM and an additional assay with
increased sensitivity for cytoplasmic staining monitored HER2
expression. All sequential samples for a patient were immuno-
stained simultaneously. Semiquantitative assessment was per-
formed by consensus of two observers blinded to patient
details (percentage positivity for Ki67 and Bcl-2; 0–3 Hercep-
TestTM scoring; H Score on a 0–300 scale for all other
markers). Staining was nuclear for ER, PR, pER, pMAPK and
Ki67, cytoplasmic for Bcl-2, or plasma membrane (EGFRm,
HER2m) and cytoplasmic (EGFRc, HER2c). Any samples with
insufﬁcient cellularity or nonspeciﬁc staining after each assay
were excluded. The IHC staining and assessment (using stand-
ardized and internally validated protocols) is further detailed
in Supplementary Assay Information.
Focussing on the All-patient (n5 32) and clinical beneﬁt
(CB, n5 26) groups, early progressors (EP, n5 11) and con-
tinuing responders/late progressors (CONR/LP, n5 13) as
deﬁned in Table 1, biomarker changes were analyzed between
matched T1, T2, T3 and T4 biopsies in each patient using
Friedman’s ANOVA and Wilcoxon Paired Signed-Rank test
(signiﬁcance p <= 0.05). At each biopsy time point, Kaplan–
Meier analysis (Log rank test) determined biomarker rela-
tionship to DoR on fulvestrant using the respective median
staining cut-point (Supporting Information Table S2), with
disease progression on fulvestrant as the event. Staining rela-
tionship to DoCB was determined by Mann Whitney analysis
in EP versus CONR/LP. Patient numbers were insufﬁcient
for analysis (i) within de novo fulvestrant resistant disease
(PD, n5 6) or within speciﬁc CB patient subgroups and (ii)
with respect to DoR according to T4 biomarker expression.
Results
Figure 1 (with Supporting Information Table S2) shows the
median staining obtained for the IHC biomarkers at each treat-
ment time-point in the All-patient group. Staining data for
individual patients are shown in Figure 2. Supporting Informa-
tion Tables S3 and S4 provide median staining data for the CB
(clinical beneﬁt) and the EP (early progressors) and CONR/LP
(continuing responders/late progressors) cohorts, respectively.
Table 2 summarizes the key statistical ﬁndings for the bio-
markers in these various patient cohorts during treatment.
ER expression, activity and ER-regulated proteins
PR and Bcl-2
ER declined signiﬁcantly versus T1 at all fulvestrant treatment
time-points and in all cohorts reaching its lowest levels by T3
which were then generally maintained at T4 (Figs. 1a and 2a;
Table 2; Supporting Information Tables S2–S4). No patient
had lost all ER at relapse even in the longest T1-T4 interval of
60.7 months. An example of sequential biopsy ER immuno-
staining is provided in Supporting Information Fig. S1a.
PR was detectable in most patients at T1. Despite small
numbers of progressive disease patients, it was noted that PR
was signiﬁcantly lower than in CB patients at T1 (p5 0.012),
Table 1. Criteria defining quality and duration of response to
fulvestrant
QUALITY OF CLINICAL RESPONSE
Patients were assessed clinically every 6 weeks for the first 6
months using bi-dimensional calliper measurements of their tumour
and then at 12 weekly intervals (as per UICC criteria):
CR5Complete response to fulvestrant
PR5 Partial response to fulvestrant
SD5Stable disease on fulvestrant
CB5 clinical benefit on fulvestrant, i.e., Complete or Partial response
or Stable disease for >= 6 months
PD5progressive disease, i.e., progression of disease on fulvestrant
within 6 months
CLINICAL RESPONSE DURATION
Median DoR5median duration of response between fulvestrant
treatment commencement and disease progression on this agent for
All-patients
Median DoCB= median duration of response to fulvestrant in
patients with CB
CB patients were also subdivided into EP (early progressors, i.e., CB
tumours progressing prior to median DoCB on fulvestrant) or CONR/
LP sub-sets (continuing responders/late progressors, i.e., CB
tumours with fulvestrant responses exceeding median DoCB, includ-
ing those progressing on fulvestrant after this time).
Two CB patients with follow-up <median DoCB were excluded from
EP versus CONR/LP analyses.
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with three of the 4 PR-negative tumours being progressive
disease. Although falls were generally modest at T2, by T3
PR had declined in all of the patient cohorts versus T1 (Figs.
1b and 2b; Table 2; Supporting Information Tables S2–S4).
Supporting Information Fig. S1b shows an example of
sequential biopsy PR immunostaining. Interestingly, PR fall
at T2 was more substantial and by T3 reached signiﬁcance in
EP patients, contrasting a more modest decline in the longer-
responding CONR/LP patients (Table 2; Supporting Informa-
tion Table S4). PR remained signiﬁcantly lower at T4 than
T1 in the All-patient cohort (Figs. 1b and 2b; Supporting
Information Table S2) and CB cohort following matched
analysis (Table 2), with complete PR loss in one third of
tumours (as predominantly seen in Supporting Information
Fig. S1b). However, three tumours maintained substantial PR
(H-Score >= 100) at T4 exceeding T3 (Fig. 2b).
Bcl-2 was detected in all T1 samples irrespective of
response status. Bcl-2 fell signiﬁcantly in 58% patients by T3
(Figs. 1c, 2c; Table 2; Supporting Information Tables S2, S3
and Supporting Information Fig. S1c). Signiﬁcant Bcl-2
decreases were apparent in early progressors at both T2 and
T3, but there was no T2 fall in CONR/LP patients and a
marginal decline by T3 (Table 2; Supporting Information
Table S4). Some T3-T4 Bcl-2 recovery occurred in approxi-
mately 65% patients (Fig. 2c), reaching signiﬁcance in about
70% CB so there was no signiﬁcant staining difference
Figure 1. Box and whisker plots displaying marker profile (unmatched data) across T1 (pre-treatment) and T2, T3 and T4 (6 week, 6 month
and at progression on fulvestrant, respectively) for the All-patient cohort. (a) ER H Score; (b) PR H Score; (c) % Bcl-2; (d) pER (serine 118
phosphorylation) H Score; (e) HercepTestTM score; (f) HER2m (membrane) and HER2c (cytoplasmic) H Scores; (g) pHER2m (membrane) and
pHER2c (cytoplasmic) H Scores; (h) EGFRm (membrane) and EGFRc (cytoplasmic) H Scores; (i) pEGFRm (membrane) and pEGFRc (cytoplas-
mic) H Scores; (j) pMAPK H Score and (k) % Ki67 staining (o5 outliers and *= extreme outliers with values more than 33 the box height).
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Figure 1. (Continued).
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
150 Biological effects of fulvestrant in breast cancer
Int. J. Cancer: 138, 146–159 (2016) VC 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC
Figure 2. Line plots of individual changes in markers (matched data) across T1 (pretreatment) and T2, T3 and T4 (6 week, 6 month and at pro-
gression on fulvestrant respectively) for each patient. Wilcoxon Paired Signed-Rank test compared staining between time-points using paired
sample data from each patient. Significance between T1-T2, T1-T3, T2-T3, T1-T4 or T3-T4 is indicated by , , , and , respectively. To
aid visualisation of profile over the multiple time-points in these plots, marker data have been connected in the same patient if any sample
was unavailable. (a) ER H Score (T1-T2, T1-T3, T2-T3 falls p<0.001; T1-T4 fall p50.001); (b) PR H Score (T1-T3 p<0.001, T2-T3 falls
p50.006; T1-T4 fall p50.012); (c) Bcl-2% positivity (T1-T3 fall p50.007; T3-T4 increase p50.066); (d) pER (serine 118 phosphorylation) H
Score; (e) HER2m (membrane) and HER2c (cytoplasmic) H Scores; (f) pHER2m (membrane) and pHER2c (cytoplasmic) H Scores (NB. no meas-
urable staining was detected in any sample from 20 patients for HER2c and 16 patients for pHER2c); (g) EGFRm (membrane) and EGFRc (cyto-
plasmic) H Scores; (h) pEGFRm (membrane; T1-T3 fall p50.024; T3-T4 increase p50.012) and pEGFRc H Scores (cytoplasmic; T3-T4 increase
p50.041); (i) pMAPK H Score (T1-T3 fall p50.019); (j) Ki67% positivity (T1-T2 p50.001, T1-T3 p50.012, T2-T3 falls p50.048; T1-T4 fall
p50.028); (k) Tumour cellularity % (T1-T2 fall p50.019; T1-T3 fall p50.003; T3-T4 increase p50.065).
Figure 2. (Continued).
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Table 2. Summary of significant results from matched statistical analysis of biomarkers in the fulvestrant treated series for the All-patients,
CB (clinical benefit), EP (early progressors) and CONR/LP (continuing responders/late progressors) cohorts
All-patients CB EP and CONR/LP
ER HScore T1-T2-T3: ER fall, p<0.001
T1-T2 or T1-T3: ER fall, p<0.001
T2-T3: ER fall, p<0.001
T1-T4: ER fall, p50.001
T1-T2-T3: ER fall, p<0.001
T1-T2 or T1-T3: ER fall,
p<0.001
T2-T3: ER fall, p<0.001
T1-T4: ER fall, p50.004
EP ﬁ ER fall,
T1-T2: p50.018
T1-T3: p50.003
T2-T3: p50.028
CONR/LP ﬁ ER fall,
T1-T2: p50.003
T1-T3: p50.005
T2-T3: p50.008
PR HScore T1-T2-T3: PR fall, p<0.001
T1-T2: PR unchanged in
many patients
T1-T3: PR fall, p<0.001
T2-T3: PR fall, p50.006
T1-T4: PR fall, p50.012
T1-T2-T3: PR fall, p<0.001
T1-T2: PR unchanged in
many patients
T1-T3: PR fall, p50.008
T2-T3: PR fall, p50.042
T1-T4: PR fall, p50.018
EP ﬁ PR fall,
T1-T3: p50.008
T2-T3: p50.042
CONR/LP ﬁ PR fall,
T1-T3: p50.093
T2-T3: p50.063
Bcl-2% T1-T2: Bcl-2 unchanged in
many patients
T1-T3: Bcl-2 fall, p50.007
T3-T4: Bcl-2 rise in 64%
patients, p50.066
T1-T2: Bcl-2 unchanged
in many patients
T1-T3: Bcl-2 fall, p50.012
T3-T4: Bcl-2 rise in 70%
patients, p50.04
EP ﬁ Bcl-2 fall,
T1-T2; p50.042
T1-T3: p50.028
CONR/LP ﬁ
T1-T2: unchanged
T1-T3: p50.138
pER HScore 54% patients show decrease
by T3, but no dominant change
in pER during treatment
Some decreases in patients
by T3, but no dominant change
in pER during treatment
Some decreases in patients
by T3, but no dominant
change in pER during treatment
HER2 expression:
HercepTestTM or
HER2m and HER2c
H Score
HER2 activity:
pHER2m and HER2c
H Score
HercepTestTM:
T1-T2-T3: HER2 rise, p< 0.001
T1-T3: HER2 rise, p50.034
HercepTestTM:
T1-T3: HER2 rise, p50.034
HER2c assay:
T2-T3: HER2c rise, p50.041
pHER2m assay:
EP ﬁ pHER2m rise,
T2-T3: p50.078
EGFR expression:
EGFR activity:
pEGFRm andpEGFRc
H Score
EGFR: no dominant change
T1-T3: pEGFRm fall, p50.024
T3-T4: pEGFRm rise in
67% patients, p50.012
T3-T4: pEGFRc rise in
50% patients, p50.041
EGFR: no dominant change
T1-T3: pEGFRm fall, p50.028
T3-T4: pEGFRm rise in 72%
patients, p50.011
T3-T4: pEGFRc rise in 55%
patients, p50.041
EGFR: No dominant change
Some falls but no dominant
change in pEGFR
pMAPK Hscore T1-T3: pMAPK fall, p50.019 T1-T3: pMAPK fall, p50.028 Some falls but no dominant
change in pMAPK
Ki67% T1-T2-T3: Ki67 fall, p<0.001
T1-T2: Ki67 fall, p50.001
T1-T3: Ki67 fall, p50.012
T2-T3: Ki67 fall, p50.048
T1-T4: Ki67 fall, p50.028
T1-T2-T3-T4: Ki67 rise in
45% patients, p50.077
T1-T2-T3: Ki67 fall, p<0.001
T1-T2: Ki67 fall, p50.001
T1-T3: Ki67 fall, p50.012
T2-T3: Ki67 fall, p50.048
T1-T4: Ki67 fall, p50.074
EP ﬁ Ki67 fall
T1-T2-T3: p50.032
T1-T2: p50.027
T1-T3: p50.033
T2-T3: unchanged
CONR/LP ﬁ
Ki67 fall
T1-T2-T3: p50.003
T1-T2: p50.021
T1-T3: p50.007
T2-T3: p50.021
Tumour
cellularity %
T1-T2-T3: cellularity fall, p50.007
T1-T2: cellularity fall, p50.019
T1-T3: cellularity fall, p50.003
T3-T4: cellularity rise in
50% patients, p50.065
T1-T2-T3: cellularity fall, p50.007
T1-T2: cellularity fall, p50.01
T1-T3: cellularity fall, p50.004
T3-T4: cellularity rise
in 46% patients, p50.088
EP ﬁ cellularity fall
T1-T2-T3: p50.018
T1-T2: p50.045
T1-T3: p50.028
CONR/LP ﬁ cellularity fall
T1-T2-T3: p50.067
T1-T2: p50.057
T1-T3: p50.027
Statistical analyses were performed in SPSSTM using Friedman’s ANOVA for T1-T2-T3 and T1-T2-T3-T4 and Wilcoxon Paired Signed-Rank test for all
paired analysis. T1= pre-treatment; T2= 6 week fulvestrant treatment; T3= 6 month fulvestrant treatment; T4= fulvestrant progression; c= cytoplasmic;
m= membrane; CB= clinical benefit patient group; EP= early progressor patient group; CONR/LP= continuing responder/late progressor patient group.
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between T1 and T4 (Table 2; Supporting Information Table
S3). Supporting Information Figure S1c shows such Bcl-2
staining.
ER activity (phosphorylated serine 118), again detected in
all T1 samples irrespective of response status, decreased very
modestly in 54% patients by T3 on matched analysis (Fig. 2d;
Table 2). Supporting Information Figure S1d provides an
example of such sequential biopsy pER staining. No patient
was pER negative at T4 and there was no consistent pattern
of pER change at this time-point (Figs. 1d, 2d; Supporting
Information Tables S2 and S3). Spearman’s analysis showed
that pER weakly correlated with ER expression at all time-
points (T1 p5 0.018, r5 0.42; T2 p5 0.054, r5 0.38; T3
p5 0.025, r5 0.46; T4 p5 0.003, r5 0.74) and with Bcl-2 at
T1 (p5 0.005, r5 0.5) and T3 (p5 0.008, r5 0.53).
Kaplan–Meier analysis revealed no signiﬁcant relationship
between ER expression or activity and DoR on fulvestrant at
any time-point or at T1 or T3 for PR or Bcl-2 (data not
shown). However, DoR was signiﬁcantly prolonged where PR
or Bcl-2 staining at T2 exceeded the median cut-point [Figs.
3a (p5 0.008) and 3b (p5 0.01), respectively], while Bcl-2
level in CONR/LP patients also signiﬁcantly exceeded early
progressors at this time-point (p5 0.01; Supporting Informa-
tion Table S4).
HER2, EGFR and their activated forms (pHER2, pEGFR)
Generally, very modest HER2 membrane (HER2m) expres-
sion and activity (pHER2m) were detectable in this series,
with little or no HER2 cytoplasmic (HER2c, pHER2c) stain-
ing (Figs. 1e-g; Figs. 2e and 2f; Supporting Information
Tables S2–S4). Staining with HercepTestTM was seen at T1 in
17% patients (5 of the 29 patients with adequate Hercep-
TestTM data), including three 31 samples comprising one CB
and two PD. T1 samples with HercepTestTM score >0 also
showed some positivity for HER2m/pHER2m. There were
few signiﬁcant changes in HER2 expression or activity with
fulvestrant in this patient series (Figs. 1e-g; Figs. 2e and 2f;
Supporting Information Tables S2–S4; Supporting Informa-
tion Figs. S1e and S1g). HercepTestTM staining increased in
29% patients by T3 (Fig. 1e). These increases reached signiﬁ-
cance by matched analysis in the whole series and in CB
patients (Table 2) but were modest (HercepTestTM score 0-
to-1: n5 2; 0/1-to-2: n5 3) with no 31 gains. An additional
HER2 expression assay also detected T2-T3 HER2c increases
in approximately 25% paired samples from the whole series
(Figs. 1f and 2e), although many remained HER2c negative.
This increase reached signiﬁcance in CB (Table 2), where
there were additionally occasional modest T3 increases in
HER2m and pHER2 on matched analysis in approximately
40% of patients (Figs. 2e and 2f; Supporting Information
Figs. S1f and S1h). There was a trend for a T2-T3 pHER2m
increase in 60% EP samples (Table 2). HER2m expression
(p5 0.028, r5 0.45) and activity at T3 (p5 0.016, r5 0.49)
directly associated with pER by Spearman’s analysis.
Although occasional samples showed changes (including
slight HER2c and pHER2c increases and one patient with a
0-to-2 HercepTestTM score increase), there was no dominant
pattern in HER2 expression/activity at relapse with generally
modest levels in T4 samples (Figs. 1f and 1g; Figs. 2e and 2f;
Supporting Information Tables S2 and S3; Supporting Infor-
mation Figs. S1e and S1g).
This series also had low EGFR membrane (EGFRm) and
cytoplasmic (EGFRc) staining, excepting four patients at T1 (H
Score>=100) of which three were CB. Some EGFR changes
were seen in samples during treatment but membrane H Scores
remained very low (median <=10) along with modest cytoplas-
mic signals (Figs. 1h and 2g; Supporting Information Fig. S1i;
Supporting Information Tables S2–S4). There was no dominant
pattern of EGFR expression change on matched analysis at any
time-point (Fig. 2g; Table 2). Similarly, pEGFR levels were gen-
erally very low (median <=10; Fig. 1i; Supporting Information
Tables S2–S4). There was signiﬁcant loss of detectable pEGFRm
staining in approximately 50% patients by T3 including in CB
(Figs. 1i 2h; Table 2; Supporting Information Fig. S1j). While
still generally at extremely low levels at T4 (median H Score
<=10), small signiﬁcant increases were subsequently detected
for pEGFRc or pEGFRm in 50–67% T4 samples including 72%
of CB (Figs. 1i and 2h; Table 2; Supporting Information Tables
S2 and S3; Supporting Information Fig. S1j). Tumours with
weakly detectable T3-T4 increases in pEGFRm also showed
modest HER2m increases (p5 0.027) and Spearman’s analysis
revealed direct associations at T4 between EGFR activity and
pER (p5 0.006), Bcl-2 (p5 0.055) and Ki67 (p5 0.047).
Kaplan–Meier analysis was not meaningful for total EGFR
or HER2 expression since this ER1 series contained very few
highly HER2 or EGFR expressing tumours. Patients with any
pHER2c positivity at T1 had a shortened DoR (p5 0.018;
Fig. 3c) but no relationship was seen for pHER2m. Although
levels were extremely low, a shortened DoR was also
observed for patients with any detectable pEGFRm at T2
(p5 0.007; Fig. 3d). pHER2c (p5 0.051) and pEGFRm
(p5 0.037) were also weakly increased in EP versus CONR/
LP patient samples at these respective time-points.
MAPK (ERK1/2) activity
Nuclear MAPK activity (pMAPK), detected at moderate levels
in T1 samples irrespective of response status, signiﬁcantly
declined in approximately 65% of All-patient and CB samples
at T3 (Figs. 1j, 2i; Table 2; Supporting Information Tables S2
and S3; Supporting Information Fig. S1k). Some falls were also
apparent in EP and CONR/LP patients (Supporting Informa-
tion Table S4). Such tumours with a pMAPK decrease by 6
months (n5 16) also showed signiﬁcant decline in pEGFRm
(p5 0.013), Bcl-2 (p5 0.031) and Ki67 (p5 0.003). Subse-
quent non-signiﬁcant nuclear pMAPK increases occurred in
approximately 50% T4 samples versus T3 (Figs. 1j, 2i; Sup-
porting Information Tables S2 and S3; Supporting Information
Fig. S1k). Kaplan–Meier analysis revealed no relationship
between pMAPK and DoR (data not shown).
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Figure 3. Kaplan–Meier association (using the median staining level from Supporting Information Table S2 at each time point as a cut-
point) between biomarkers and duration of response (DoR) to fulvestrant (*p<0.05 using Log Rank test). Responses to any other treat-
ments following fulvestrant progression were not a component of these response data. (a) PR H Score at T2; p50.008 for higher PR [mean
DoR= 48.2 months (95% CI=36.9–59.5; n514)] vs. lower PR [mean DoR= 23.4 months (95% CI= 11.6–35.1; n514)]; (b) Bcl-2% at T2;
p50.01 for higher Bcl-2% [mean DoR= 48.4 months (95% CI=38.5–58.4; n513)] vs. lower Bcl-2% [mean DoR= 27.5 months (95% CI=
15.3–39.6; n514)]; (c) pHER2c (cytoplasmic) H Score at T1; p50.018 for any detectable pHER2c [mean DoR= 16.8 months (95% CI=
10.1–23.5); n59] versus no pHER2c [mean DoR= 39.1 months (95% CI= 28.5–49.7; n522)]; (d) pEGFRm (membrane) H Score at T2;
p50.007 for any detectable pEGFRm [mean DoR= 21.1 months (95% CI= 12.5–29.7; n511)] vs. no pEGFRm [mean DoR= 48.1 months
(95% CI= 36.0–60.3; n516)]; (e) Ki67% at T1; p50.01 for higher Ki67 [mean DoR= 22.2 months (95% CI= 13.2–31.3; n515)] vs. lower
Ki67 [mean DoR= 43.1 months (95% CI= 30.6–55.5; n516)]; (f) Ki67% at T2; p50.027 for higher Ki67 [mean DoR= 24.7 months (95%
CI= 11.6–37.9; n512)] vs. lower Ki67 [mean DoR= 47.1 months (95% CI= 36.2–58.0; n515)].
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Proliferative activity (Ki67)
Ki67 staining was modest for most samples, with signiﬁcant
decreases across T1-T2-T3 during fulvestrant treatment in all
groups (Figs. 1k and 2j; Table 2; Supporting Information Tables
S2–S4; Supporting Information Fig. S1l). T2 and T3 Ki67 posi-
tivity was signiﬁcantly lower than T1 in up to 79% patients for
all groups (Fig. 2j; Table 2). Tumour cellularity also decreased
during fulvestrant response with T2 and T3 level signiﬁcantly
lower than T1 on matched analysis (Table 2; Fig. 2k; Support-
ing Information Tables S2–S4). There was a further very small
but signiﬁcant T2-T3 Ki67 fall in approximately 60% of the
All-patient and CB cohorts (Figs. 1k and 2j; Table 2). Interest-
ingly, this continued T2-T3 decline was only seen in the
longer-responding CONR/LP cohort and not in early progres-
sors, where by T3 there was an indication of some modest
recovery in proliferation (Table 2; Supporting Information
Table S4). Although T4 Ki67 remained a little lower than T1
for approximately 70% patients (Figs. 1k, 2j; Table 2) there was
partial recovery in Ki67 in some T4 samples (Table 2: T1-T2-
T3-T4 p5 0.077; Fig. 2j; Supporting Information Tables S2 and
S3; Supporting Information Fig. S1l) with T3-T4 increases in 5/
11 (about 45%) CB patients. Tumour cellularity also recovered
in approximately 50% patients at T4 (Fig. 2k; Table 2; Support-
ing Information Tables S2 and S3).
Kaplan–Meier analysis demonstrated a signiﬁcantly short-
ened DoR at T1 (p5 0.01) for patients with Ki67 above the
median cut-point (>18% staining; Fig. 3e). Concordantly,
Ki67 was at a signiﬁcantly higher level in early progressors
versus the longer-responding CONR/LP patient cohort at T1
(p5 0.037; Supporting Information Table S4). Multivariate
analysis using Cox’s proportional hazards model [considering
univariate-signiﬁcant covariates baseline disease site and
grade (Supporting Information Table S1), T1 pHER2c and
T1 Ki67 (Figs. 3c and 3e)] showed T1 Ki67 was an independ-
ent predictor of fulvestrant DoR (p5 0.012), with high stain-
ing patients having a hazard 6.6-fold that of low staining
patients (Supporting Information Table S5). While levels
were very low at T2 and T3 in CB patients, retention of any
Ki67 at T2 was also adversely associated with DoR
(p5 0.027; Fig. 1f). With a trend at T2 (p5 0.071), early pro-
gressors had a signiﬁcantly higher Ki67 level at T3 versus the
longer-responding CONR/LP cohort (p5 0.043; Supporting
Information Table S4).
Discussion
This is the ﬁrst clinical investigation of the biological impact
of short (6 weeks), medium (6 months) and long-term (>2
years) fulvestrant (250 mg/month) through to acquired resist-
ance using sequential biopsies. In this ER1 breast cancer
series, there was superior beneﬁt for fulvestrant, with 81%
CB and a median DoR of 25.8 (1.77–60.73) months, com-
pared with previous reports of up to 60% CB and 4-18
months response.3,4,6,26,27 Our series had substantial ER-
regulated proteins, modest EGFR/HER2 signaling and ele-
vated Ki67 expression, a proﬁle similarly equated to better
outcome for other anti-hormones.
The ER downregulation we observed with fulvestrant at 6
weeks is consistent with previous short-term (<3 weeks) pre-
surgical primary breast cancer studies for short-acting (6 or
18 mg/daily subcutaneously28) and long-acting formulations
(50–250 mg/month intramuscularly7). ER decline is also seen
in the neoadjuvant (4 and 16 weeks treatment) setting.8 Such
studies demonstrated that ER downregulation is fulvestrant
dose-dependent but we demonstrate here that treatment
duration is a further inﬂuence since superior ER decline was
achieved by 6 months (the timeframe for 250 mg fulvestrant
to reach steady-state2). Critically, we have found that ER level
at all time-points fails to relate to fulvestrant response.
Indeed, by 6 weeks virtually every tumour had signiﬁcant ER
decline irrespective of patient response status or duration
[occurring in CB (clinical beneﬁt), PD (progressive disease),
EP (early progressors) and CONR/LP patients (continuing
responders/late progressors)]. The CONFIRM trial5 demon-
strated a longer duration of CB while the NEWEST trial8
reported greater ER depletion for 500 mg versus 250 mg ful-
vestrant. However, our ﬁndings indicate that despite ER
being the required target for fulvestrant and ER downregula-
tion a hallmark of this agent’s mechanism of action, parame-
ters other than receptor level must determine extent of
clinical fulvestrant response in ER1 tumours.
To determine whether ER activity was more informative,
we monitored fulvestrant impact on ER phosphorylation and
two ER-regulated proteins. Although patient number pre-
cluded meaningful analysis of pER or Bcl-2, PD patients
were commonly PR negative at baseline suggesting classical
estrogen/ER signaling is needed to achieve CB with fulves-
trant. However, these PR ﬁndings remain clinically contro-
versial.29,30 Moreover, tissue inhibitor of metalloproteinases 1
(TIMP-1) overexpression has been noted to promote PR loss
and fulvestrant resistance in vitro potentially via modifying
nonclassical ER activity.31 Fulvestrant promoted a time-
dependent fall in PR and Bcl-2 (and modest pER decline in
about 50% patients) in our series by 6 months. Previous
shorter-term studies using 250 mg fulvestrant have reported
signiﬁcant PR decline,7,32 but our ﬁndings again equate better
with the timeframe for 250 mg dose steady state2 and corrob-
orate with NEWEST trial observations that 500 mg is
required to signiﬁcantly repress PR during short-term treat-
ment.8 We found that baseline ER activity, PR and Bcl-2 did
not relate to duration of CB, and in the longer-responding
(CONR/LP) patients PR and Bcl-2 decline during treatment
was at best small. This suggests that an extended DoR with
fulvestrant does not equate with superior blockade of these
particular ER-regulated proteins.
We also examined whether fulvestrant inﬂuenced ER/GF
pathway cross-talk and if this determined response. Experi-
mentally, endocrine agents can deplete ER-regulated growth
factor ligands for upstream receptors of MAPK,22 and after 6
months fulvestrant we noted that any membrane EGFR
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activity was lost and MAPK (ERK1/2) activity decreased.
Such pMAPK depletion may contribute toward the small fall
in phosphorylated serine 118 ER seen in some fulvestrant-
treated patients since pMAPK activates this AF-1 residue.22
This pMAPK fall after 6 months fulvestrant was paralleled by
Ki67 decline, so inhibition of ER/MAPK cross-talk may con-
tribute towards fulvestrant’s anti-proliferative effect, as
reported in some ER1 models.33,34 However, as T3 pMAPK
and pEGFR decreases occurred in only about one-half of CB
patients, were extremely modest for pEGFR and were unre-
lated to outcome, further mechanisms must contribute to ful-
vestrant response in patients.
Importantly, low baseline Ki67 (<=median 18%) signiﬁ-
cantly associated with durable fulvestrant response in univari-
ate and multivariate analysis. The subsequent fall in
proliferation in many patients by 6 weeks was consistent
with previous short-term fulvestrant studies7,8,28 but we also
determined that patients with the very lowest resultant prolif-
eration (<=median 5%) had a longer DoR. In the IMPACT
trial,35,36 reduced proliferation at 2 weeks similarly predicted
for extended disease-free interval with tamoxifen or anastro-
zole presurgically. Proliferation suppression by fulvestrant
was also reported in the neoadjuvant NEWEST trial8 with
lowest Ki67 achieved using the clinically superior 500 mg
dose.5 We also found that depletion of proliferation was
apparent with longer-term fulvestrant in many CB patients.
By 6 months, there was a very small, continued Ki67 decline
in the longer-responding CONR/LP group contrasting partial
recovery in early progressors. Thus, patients with the very
lowest Ki67 after 6 months fulvestrant demonstrated superior
response. Although further veriﬁcation (including at 500 mg)
is required, we propose that measuring this proliferation
marker could have clinical predictive utility both to deter-
mine patients likely to substantially beneﬁt from fulvestrant
and as a quantitative measure of response.
We also report for the ﬁrst time the tumour biomarker
proﬁle on acquisition of fulvestrant resistance in patients. Ki67
recovered in some clinical relapse samples compared with 6
month’s treatment and this is likely to contribute towards
tumour re-growth (evidenced by increased cellularity). Fre-
quent Bcl-2 recovery suggests increased cell survival also plays
a part. Low ER levels were retained at relapse, as seen in some
acquired resistant models developed after 3–12 months fulves-
trant treatment of ER1 cells.14 Several studies37–39 suggest that
this residual ER may be functional in some patients. Cheung
et al.39 reported CB following further endocrine treatment in
46% (13/28) and 12% (3/26) of patients who had initial CB or
PD respectively on fulvestrant, including responses in seven
patients that overlap with our series and retain ER at fulves-
trant relapse. The persistent low levels of ER activity, PR and
Bcl-2 that we observed in fulvestrant relapse samples and the
ER phosphorylation and Bcl-2 detectable at pretreatment in
PD patients provide further evidence for functional ER in
some fulvestrant resistant tumours. This begs the question
whether an increased dosage of fulvestrant might further
deplete ER signaling and improve response, and provides
rationale for development of more potent ER-downregulators.
In further support, superior ER depletion was seen with
500 mg fulvestrant both in NEWEST8 (vs. 250 mg examined
up to 4 weeks) and Study 57.40 Treatment at 500 mg was also
associated with improved DoCB and overall survival in CON-
FIRM5 and increased time to progression in the FIRST trial,9,10
the latter also recently reporting better overall survival with
fulvestrant versus anastrozole.41 Nevertheless, as Cheung
et al.39 observed insensitivity to further endocrine agents in
54% of patients with initial CB on fulvestrant, a signiﬁcant
proportion of fulvestrant relapse patients may be
ER-independent despite retention of ER. Moreover, some
cell models reveal more prolonged (>2 years in vitro) fulves-
trant can promote complete ER protein and mRNA loss.42
Theoretically, while ER positivity is a stable phenotype over
the treatment window of the current study with 250 mg
drug, further prolonging fulvestrant might ultimately pro-
mote an undesirable ER negative phenotype.
Increased EGFR/HER2 and MAPK signaling cross-talks
with ER AF-1, promotes PR loss and drives tamoxifen or
estrogen deprivation resistance in vitro.43 It is also detectable
in some clinical samples on tamoxifen progression.44,45 Here,
very modest increases in EGFR activity occurred at relapse in
approximately 65% fulvestrant treated patients versus 6
months, associating with HER2, pER, Bcl-2 and proliferation.
pMAPK also modestly recovered and PR was lost in about
one-third of relapse patients. Furthermore, although PD
patients were few, two were HER21 and one had high EGFR
at pretreatment. Anti-estrogen induced EGFR/HER2 signaling
can begin to emerge during response in ER1 cells in
vitro.14,33,34 Here, HercepTestTM score modestly increased in
about one-quarter of fulvestrant-treated patients by 6 months
and HER2 activity also weakly increased (particularly in early
progressors) and correlated with pER. Along with preclinical
studies,19,33,34,46 our ﬁndings suggest such GF signaling and its
cross-talk with residual ER might modestly contribute towards
limiting response in a small number of fulvestrant-treated
patients. However, HER2 induction with fulvestrant was infre-
quent, relapse was not paralleled by substantially increased
EGFR/HER2/MAPK activity, and PD did not obviously associ-
ate with such signaling since one ER1 HercepTestTM positive
patient and three patients with substantial baseline EGFR had
clinical beneﬁt on fulvestrant. These ﬁndings suggest lack of a
central role for HER2/EGFR signaling in clinical fulvestrant
resistance and explain recent trials showing no beneﬁt of com-
bining fulvestrant with lapatinib47 or geﬁtinib.48 Our ﬁndings
also add to evidence that fulvestrant can be considered for
HER2 or EGFR overexpressors.29,49 For most patients, addi-
tional pathways clearly drive fulvestrant progression and pre-
clinical data are implicating potential players including erbB
receptors,13,16 PI3K/AKT/mTOR, Src kinase17,18 and TIMP-
1.31 IHC in this sequential fulvestrant sample series is now
continuing for further elements which should help interpret
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ongoing trials, including fulvestrant alongside PI3K or AKT
inhibitors or with everolimus.50
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